Early Myoinositol Supplementation Improves Neonatal Birth Outcomes: Suggests Study
A recent retrospective analysis reveals that initiating 4 g of daily myoinositol supplementation before the 12th week of pregnancy can slash the incidence of fetal growth restriction by 60%, significantly optimizing maternal glycemic control and enhancing neonatal birth weights, as published in Indian Obstetrics & Gynaecology in September 2025.
Affecting approximately 5% to 10% of pregnancies worldwide, fetal growth restriction (FGR) remains a primary driver of perinatal mortality and long-term metabolic disorders in adulthood, yet there is currently limited data on preventative pharmacological measures. Building on previous research that identified myoinositol as a potent insulin-sensitizing agent capable of reducing neural tube defects and gestational diabetes, Dr. Ganesh Pandit from Mamta Maternity Hospital and colleagues from Apollo Fertility sought to address this clinical gap by evaluating the efficacy of myoinositol in preventing FGR.
Therefore, the retrospective, hospital records-based cohort study analyzed 300 singleton pregnancies at Mamta Maternity Home and Apollo Fertility in Borivali, Mumbai, between 2020 and 2024 to determine the impact of early intervention. The study population was divided into Group A, receiving 4 g/day of myoinositol plus 400 mcg of folic acid, and Group B, receiving only routine folic acid and antenatal care starting before the 12th week of gestation. Researchers utilized chi-square and t-tests to measure the primary endpoint of FGR incidence—diagnosed via Royal College of Obstetricians and Gynecologists (RCOG) guidelines—while excluding women with pre-existing diabetes, hypertension, multiple pregnancies, or known genetic fetal abnormalities.
Key clinical findings of the study include:
Drastic FGR Reduction: The study demonstrated that myoinositol intervention slashed FGR rates to 4% compared to 10% in the control group, representing a 60% risk reduction (RR 0.4).
Superior Glycemic Control: Supplemented patients achieved significantly lower mean Hemoglobin A1c (HbA1c) levels of 5.2% compared to 5.8% in the control cohort, indicating improved metabolic stability (p = 0.001).
Enhanced Birth Weight: Neonates in the myoinositol group exhibited a higher mean birth weight of 3.2 kg versus 2.8 kg in the control group, likely due to optimized placental function (p=0.004).
Reduced NICU Admissions: Maternal supplementation led to a nearly 50% decrease in Neonatal Intensive Care Unit (NICU) admissions, dropping from 15% in the control group to just 8% (RR 0.53).
Lowered Glucose Levels: Post-intervention Oral Glucose Tolerance Test (OGTT) values were significantly lower at 115 mg/dL in the study group compared to 135 mg/dL in the control group, further supporting improved glucose metabolism. (p=0.005).
The results suggest that 4 grams of myoinositol per day is a potent and effective intervention for preventing FGR and other associated pregnancy complications, as evidenced by the 60% reduction in growth restriction. This improvement in fetal growth and neonatal outcomes is likely driven by the supplement's ability to enhance insulin sensitivity and reduce maternal inflammation.
Thus, the clinicians may consider the early introduction of myoinositol as a safe and effective metabolic support tool to improve placental function and overall neonatal health.
While these results are promising, the study was limited by its single-center, retrospective design, which may restrict the generalizability of the findings across more diverse patient populations. Consequently, there is a recognized need for future multicentric, well-designed clinical trials to further validate and confirm the preventative benefits of myoinositol in obstetric practice.
Reference
Pandit G, Raut A, Gulhane S. Efficacy of Myoinositol Supplementation in Reducing Foetal Growth Restriction. Indian Obstetrics & Gynaecology. 2025;15(3):14-17.
